Reliv Introduces Breakthrough Product Targeting Degenerative Joint
Conditions
Business Wire,  Oct 28, 1996

Save a personal copy of this article and quickly find it again with
Furl.net. It's free! Save it.
CHESTERFIELD, Mo.--(BUSINESS WIRE)--Oct. 28, 1996--Reliv International
(NASDAQ: RELV), a marketer of high-quality nutritional supplements,
introduces Arthaffect(TM), a revolutionary product for the nation's 40
million people with serious joint problems and 50 million athletes
subject to joint problems.

The product contains Arthred(TM), which has been proven effective as a
treatment in Germany for thousands of sufferers (a) with a variety of
joint problems. More than $10 million in clinical trials have proven
the effectiveness of Arthred, Arthaffect's patented ingredient, in
fighting degenerative joint conditions.

Arthaffect is available in the United States exclusively through Reliv
International.

"There remains no known cure for arthritis," Dr. Carl W. Hastings,
Reliv Executive Vice President, stressed. "Traditional products on the
market simply treat the symptoms, such as pain, and often provide side
effects. In stark contrast, Arthaffect is a functional food that
focuses on the source of the problems. It is the ideal method for
caring for joints and fighting problems associated with degenerative
joint conditions, all with no known side effects."

For several years, Arthred has been widely used by thousands of
arthritis sufferers and athletes in GERMANY, where the protein-based
substance has been the subject of double-blind, parallel group clinical
trials by some of Europe's leading researchers.

Continue article
http://www.findarticles.com/p/articles/mi_m0EIN/is_1996_Oct_28/ai_18806680#continue